iSpecimen Inc. (ISPC) vs XWELL, Inc. (XWEL)

iSpecimen Inc. and XWELL, Inc. are both Diagnostics & Research companies. XWELL, Inc. is the larger, with a market value of $7.6M against $3.1M — 2.4× the size. XWELL, Inc. grew revenue faster over the last twelve months: −7.58% against −92.1%. XWELL, Inc. has the higher net margin (−117.8% vs −2,449.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, XWELL, Inc. leads on 14 and iSpecimen Inc. on 2.

Valuation

Metric ISPC XWEL Diagnostics & Research median
P/E n/m n/m 33.95
P/S 3.77 0.27 4.87
P/B 1.01 0.92 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA 0.31 n/m 25.20
EV/Sales (5.55) 0.30 5.66
Earnings yield (4,479.37%) (597.75%) (1.75%)
Free cash flow yield (617.94%) (178.41%) (0.13%)

Profitability

Metric ISPC XWEL Diagnostics & Research median
Gross margin (108.26%) 34.34% 50.89%
Operating margin (2,020.05%) (61.31%) (8.57%)
Net margin (2,449.02%) (117.83%) (6.37%)
Free cash flow margin (1,866.61%) (47.65%) 0.00%
Return on equity (968.44%) (557.21%) (2.92%)
Return on assets (170.09%) (155.10%) (6.71%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ISPC XWEL Diagnostics & Research median
Revenue growth (TTM) (92.11%) (7.58%) 7.69%
EPS growth (last fiscal year) 87.03% (38.80%) —
Revenue growth, 5-year CAGR (25.10%) 28.35% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ISPC XWEL Diagnostics & Research median
Debt to equity 0.00 0.00 0.11
Current ratio 0.82 2.27 2.02
Net debt to EBITDA 0.95 (0.08) 0.78

Dividend

Metric ISPC XWEL Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ISPC XWEL Diagnostics & Research median
Market cap 3.12m 7.64m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack